Trials / Withdrawn
WithdrawnNCT00915616
The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Mansoura University · Academic / Other
- Sex
- All
- Age
- 42 Years – 56 Years
- Healthy volunteers
- Accepted
Summary
Gastro-Esophageal Reflux Disease was defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is widely used anti-ulcer drug and has been demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in human either alone and in combination with omeprazole therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melatonin |
Timeline
- First posted
- 2009-06-08
- Last updated
- 2009-06-08
Source: ClinicalTrials.gov record NCT00915616. Inclusion in this directory is not an endorsement.